EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY-NC-ND 4.0

Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review

Chihiro Maeda, Kanako Shinada iD, Shuji Murakami iD, Haruhiro Saito iD

Thoracic Cancer · 2023-10 · 14 (28) · 2886-2889

DOI: 10.1111/1759-7714.15081 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 28.08.2023. Verfasst von Chihiro Maeda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan. Hauptthemen laut MEDLINE: Lung Neoplasms, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among epidermal growth factor receptor ( EGFR ) mutation‐positive non‐small cell lung cancers, squamous cell carcinoma is less common and shows lower responsiveness to first‐generation EGFR tyrosine kinase inhibitors (TKIs) compared to adenocarcinoma. However, the efficacy of osimertinib for squamous cell carcinoma with EGFR mutations is not well known. This study reports the case of a 57‐year‐old male diagnosed as having stage IIIC squamous cell lung cancer. Oncomine Dx Target Test identified EGFR exon19 deletion and de novo EGFR T790M mutation with variant allele frequencies (VAF) of 21.6% and 25.2%, respectively. The patient was treated with osimertinib after progression on chemoradiotherapy followed by durvalumab, and a partial response was maintained for more than 20 months. To predict EGFR‐TKI efficacy, confirmation of gene mutations and VAF using next‐generation sequencing is helpful.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsAntineoplastic AgentsCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellMaleHumansMiddle AgedErbB ReceptorsMutationProtein Kinase InhibitorsLungAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

EGFRT790Mnon-small cell lung cancerosimertinibsquamous cell carcinoma of the lung

Substanzen

ErbB ReceptorsAntineoplastic AgentsProtein Kinase InhibitorsosimertinibAcrylamidesAniline CompoundsIndolesPyrimidinesEGFR protein, human

Autor:innen und Institutionen

  • Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
  • Respiratory Disease Center, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.

ORCID-Profile: Kanako Shinada, Shuji Murakami, Haruhiro Saito

Zitieren

APA

Maeda, C., Shinada, K., Murakami, S., & Saito, H. (2023). Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review. Thoracic Cancer, 14(28), 2886-2889. https://doi.org/10.1111/1759-7714.15081

Vancouver

Maeda C, Shinada K, Murakami S, Saito H. Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review. Thoracic Cancer. 2023;14(28):2886-2889. doi:10.1111/1759-7714.15081

BibTeX
@article{Maeda2023,
  author = {Maeda, Chihiro and Shinada, Kanako and Murakami, Shuji and Saito, Haruhiro},
  title = {Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M‐positive: Case report and literature review},
  journal = {Thoracic Cancer},
  year = {2023},
  volume = {14},
  number = {28},
  pages = {2886--2889},
  doi = {10.1111/1759-7714.15081}
}
Kostenlos starten →